Abstract
Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign blepharospasm (BEB), the main, potential long-term side effect of BoNT use is the development of immunologic resistance due to the production of neutralizing antibody to the neurotoxin after repeated injections. Xeomin® (incobotulinumtoxina), a unique botulinum neurotoxin type A (BoNT/A) drug free of complexing proteins otherwise contained in all conventional BoNT/A drugs, was recently approved by US Food and Drug Administration for the treatment of cervical dystonia or blepharospasm in adults. The newly approved BoNT/A drug may overcome this limitation of previous conventional products, since it contains pure neurotoxin (150 kDa) through a manufacturing process that separates it from complexing proteins such as hemagglutinins produced by fermentation of Clostridium botulinum. Many studies have also shown that Xeomin® has the same effcacy and safety profle as complexing protein-containing products such as Botox® and is exchangeable with Botox® using a simple 1:1 conversion ratio. Xeomin® represents a new treatment option for the repeated treatment of patients with blepharospasm in that it may reduce antibody-induced therapy failure. But, long-term comparative trials in naïve patients between Xeomin® and conventional BoNT/A drugs are required to confrm the low immunogenicity of Xeomin®.
Original language | English (US) |
---|---|
Pages (from-to) | 725-732 |
Number of pages | 8 |
Journal | Clinical Ophthalmology |
Volume | 5 |
Issue number | 1 |
DOIs | |
State | Published - 2011 |
Keywords
- Blepharospasm
- Botulinum neurotoxin type a
- Complexing proteins
- Incobotulinumtoxina
- Neutralizing antibodies
- Xeominspi_sup®spii_sup